{"title":"心血管疾病患者戒烟结果的评估:来自<s:1> rkiye的回顾性队列研究","authors":"Yagmur Gokseven Arda, Guzin Zeren Ozturk","doi":"10.18332/tid/203867","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular disease (CVD) is a major preventable cause of mortality, and smoking cessation significantly reduces the risk of recurrent cardiovascular events. However, many patients continue smoking despite their CVD diagnosis. This study aims to evaluate the impact of CVD and associated factors on smoking cessation success in patients who attempted to quit smoking at least one year ago.</p><p><strong>Methods: </strong>This retrospective cohort study included patients who applied to the Smoking Cessation Clinic (SCC) between 1 May 2022 and 30 April 2023. A total of 539 eligible patients were analyzed. Data on demographics, CVD status, Fagerström test for nicotine dependence score, treatment modality (bupropion, nicotine replacement therapy, behavioral counseling), and smoking cessation outcomes were collected from medical records and confirmed via telephone interviews. Smoking cessation success was defined as complete abstinence after one year.</p><p><strong>Results: </strong>Among the participants, 145 (26.9%) had a history of CVD. The overall self-reported smoking cessation success rate after one year was 16.7%, and 17.2% in the CVD group. Bupropion users had significantly higher treatment completion rates (p=0.015). Multivariable logistic regression analysis revealed that older age (AOR=1.03; 95% CI: 1.01-1.05), higher level of education (AOR=1.84; 95% CI: 1.03-3.26), lower nicotine dependence score (AOR=0.85; 95% CI: 0.77-0.94), and treatment completion (AOR=0.13, 95% CI: 0.07-0.23) were significantly associated with smoking cessation success in the total sample. Among patients with CVD, older age (AOR=1.06; 95% CI: 1.01-1.12) and treatment completion (AOR=0.15; 95% CI: 0.05-0.43) were also associated with higher cessation success. Patients with CVD were more likely to receive non-pharmacological interventions, and behavioral counseling alone showed the highest success rate (25.0%).</p><p><strong>Conclusions: </strong>Older age and treatment adherence were significantly associated with smoking cessation success, yet overall cessation rates remained low. A CVD diagnosis alone did not significantly enhance success, highlighting the need for tailored behavioral support and structured follow-up. Optimizing cessation programs with individualized interventions may improve outcomes, particularly in high-risk CVD patients.</p>","PeriodicalId":23202,"journal":{"name":"Tobacco Induced Diseases","volume":"23 ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086687/pdf/","citationCount":"0","resultStr":"{\"title\":\"Assessment of smoking cessation outcomes in patients with cardiovascular disease: A retrospective cohort study from Türkiye.\",\"authors\":\"Yagmur Gokseven Arda, Guzin Zeren Ozturk\",\"doi\":\"10.18332/tid/203867\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Cardiovascular disease (CVD) is a major preventable cause of mortality, and smoking cessation significantly reduces the risk of recurrent cardiovascular events. However, many patients continue smoking despite their CVD diagnosis. This study aims to evaluate the impact of CVD and associated factors on smoking cessation success in patients who attempted to quit smoking at least one year ago.</p><p><strong>Methods: </strong>This retrospective cohort study included patients who applied to the Smoking Cessation Clinic (SCC) between 1 May 2022 and 30 April 2023. A total of 539 eligible patients were analyzed. Data on demographics, CVD status, Fagerström test for nicotine dependence score, treatment modality (bupropion, nicotine replacement therapy, behavioral counseling), and smoking cessation outcomes were collected from medical records and confirmed via telephone interviews. Smoking cessation success was defined as complete abstinence after one year.</p><p><strong>Results: </strong>Among the participants, 145 (26.9%) had a history of CVD. The overall self-reported smoking cessation success rate after one year was 16.7%, and 17.2% in the CVD group. Bupropion users had significantly higher treatment completion rates (p=0.015). Multivariable logistic regression analysis revealed that older age (AOR=1.03; 95% CI: 1.01-1.05), higher level of education (AOR=1.84; 95% CI: 1.03-3.26), lower nicotine dependence score (AOR=0.85; 95% CI: 0.77-0.94), and treatment completion (AOR=0.13, 95% CI: 0.07-0.23) were significantly associated with smoking cessation success in the total sample. Among patients with CVD, older age (AOR=1.06; 95% CI: 1.01-1.12) and treatment completion (AOR=0.15; 95% CI: 0.05-0.43) were also associated with higher cessation success. Patients with CVD were more likely to receive non-pharmacological interventions, and behavioral counseling alone showed the highest success rate (25.0%).</p><p><strong>Conclusions: </strong>Older age and treatment adherence were significantly associated with smoking cessation success, yet overall cessation rates remained low. A CVD diagnosis alone did not significantly enhance success, highlighting the need for tailored behavioral support and structured follow-up. Optimizing cessation programs with individualized interventions may improve outcomes, particularly in high-risk CVD patients.</p>\",\"PeriodicalId\":23202,\"journal\":{\"name\":\"Tobacco Induced Diseases\",\"volume\":\"23 \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-05-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086687/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tobacco Induced Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.18332/tid/203867\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tobacco Induced Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18332/tid/203867","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
Assessment of smoking cessation outcomes in patients with cardiovascular disease: A retrospective cohort study from Türkiye.
Introduction: Cardiovascular disease (CVD) is a major preventable cause of mortality, and smoking cessation significantly reduces the risk of recurrent cardiovascular events. However, many patients continue smoking despite their CVD diagnosis. This study aims to evaluate the impact of CVD and associated factors on smoking cessation success in patients who attempted to quit smoking at least one year ago.
Methods: This retrospective cohort study included patients who applied to the Smoking Cessation Clinic (SCC) between 1 May 2022 and 30 April 2023. A total of 539 eligible patients were analyzed. Data on demographics, CVD status, Fagerström test for nicotine dependence score, treatment modality (bupropion, nicotine replacement therapy, behavioral counseling), and smoking cessation outcomes were collected from medical records and confirmed via telephone interviews. Smoking cessation success was defined as complete abstinence after one year.
Results: Among the participants, 145 (26.9%) had a history of CVD. The overall self-reported smoking cessation success rate after one year was 16.7%, and 17.2% in the CVD group. Bupropion users had significantly higher treatment completion rates (p=0.015). Multivariable logistic regression analysis revealed that older age (AOR=1.03; 95% CI: 1.01-1.05), higher level of education (AOR=1.84; 95% CI: 1.03-3.26), lower nicotine dependence score (AOR=0.85; 95% CI: 0.77-0.94), and treatment completion (AOR=0.13, 95% CI: 0.07-0.23) were significantly associated with smoking cessation success in the total sample. Among patients with CVD, older age (AOR=1.06; 95% CI: 1.01-1.12) and treatment completion (AOR=0.15; 95% CI: 0.05-0.43) were also associated with higher cessation success. Patients with CVD were more likely to receive non-pharmacological interventions, and behavioral counseling alone showed the highest success rate (25.0%).
Conclusions: Older age and treatment adherence were significantly associated with smoking cessation success, yet overall cessation rates remained low. A CVD diagnosis alone did not significantly enhance success, highlighting the need for tailored behavioral support and structured follow-up. Optimizing cessation programs with individualized interventions may improve outcomes, particularly in high-risk CVD patients.
期刊介绍:
Tobacco Induced Diseases encompasses all aspects of research related to the prevention and control of tobacco use at a global level. Preventing diseases attributable to tobacco is only one aspect of the journal, whose overall scope is to provide a forum for the publication of research articles that can contribute to reducing the burden of tobacco induced diseases globally. To address this epidemic we believe that there must be an avenue for the publication of research/policy activities on tobacco control initiatives that may be very important at a regional and national level. This approach provides a very important "hands on" service to the tobacco control community at a global scale - as common problems have common solutions. Hence, we see ourselves as "connectors" within this global community.
The journal hence encourages the submission of articles from all medical, biological and psychosocial disciplines, ranging from medical and dental clinicians, through health professionals to basic biomedical and clinical scientists.